Lung cancer Is the leading cause of cancer death in the U.S. and worldwide. The Hsp90 chaperone isrequired for the stability of multiple oncogenic kinases that drive signaling, proliferation and survival of nonsmallcell lung cancers (NSCLCs), including mutant EGFR, Her2, B-Raf, c-Met and cdk4. Inhibitors ofHspQO will be studied including geldanamcyins such as 17-AAG, the water-soluble derivatives IPI-504 and17-DMAG, and STA-11-9090, a novel non-geldanamycin, to compare their relative potencies, to definepharmacodynamic endpoints and to conduct clinical trials in molecularly defined patient subgroups. In thefirst specific aim, these compounds will be studied in EGFR mutant NSCLC cells, including those expressingmutant EGFR harboring the T790M secondary mutation conferring erlotinib resistance. The ability of Hsp90inhibitors to deplete mutant EGFR and to suppress downstream signaling of the PI3K-Akt-mTOR-p70S6Kpathway will be assessed. The relative potencies of 17-DMAG and STA-11 -9090 will be compared to 17-AAG in isogenic cell line models in vitro, and in EGFR mutant/T790M NCI-H1975 xenografts in vivo. Theactivity of these compounds will also be evaluated in mutant EGFR-driven models of lung adenocarcinoma.In the second specific aim, the activity of Hsp90 inhibitors will be assessed in EGFR wild-type cells driven byother Hsp90 clients. Additionally, Hsp90 inhibitor-mediated depletion of IGF-1R will be evaluated in cellsexpressing EGFR: IGF-1R heterodimers to determine if there is cytotoxic synergy with erlotinib. In the thirdspecific aim, synerglsm of 17-AAG with other agents that disrupt chaperone function or Hsp70 induction willbe explored, including inhibitors of HDAC6, the proteasome or cyclin-dependent kinase 9. In the fourthspecific aim, a Phase l/ll Trial of IPI-504 will be conducted; after establishment of the maximum tolerateddose (MTD), preliminary antitumor activity will be defined in NSCLC patients harboring either EGFR mutantor wild-type tumors. A Phase I trial of STA-11-9090 will also be performed to establish the MTD .and safetyprofile, Hsp90 client depletion will be evaluated in tumor biopsy specimens and peripheral bloodnononuclear cells.In summary, survival for advanced NSCLC remains poor. Many proteins that drive lung cancer growthdepend on a chaperone called Hsp90 for their stability and function. This work will explore compounds thatinhibit Hsp90 in preclinical models and clinical trials as potential treatments for lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA090578-06
Application #
7450274
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2008-07-01
Project End
2013-06-30
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
6
Fiscal Year
2008
Total Cost
$159,120
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Sofer, Tamar; Schifano, Elizabeth D; Christiani, David C et al. (2017) Weighted pseudolikelihood for SNP set analysis with multiple secondary outcomes in case-control genetic association studies. Biometrics 73:1210-1220
Rangachari, Deepa; Le, Xiuning; Shea, Meghan et al. (2017) Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol 12:e175-e177

Showing the most recent 10 out of 263 publications